Most cited papers from Eli Lilly (Japan)

Eli Lilly (Japan)

What are the most cited papers from Eli Lilly (Japan)?

The most cited paper from Eli Lilly (Japan) is "Gemcitabine alone or in combination with cisplatin in patients with biliary tract cancer: a comparative multicentre study in Japan" (Takuji Okusaka, Kohei Nakachi, Akira Fukutomi et al., 2010), with 757 citations. Next come "Ramucirumab plus erlotinib in patients with untreated, EGFR-mutated, advanced non-small-cell lung cancer (RELAY): a randomised, double-blind, placebo-controlled, phase 3 trial" (619) and "Robust Central Reduction of Amyloid-β in Humans with an Orally Available, Non-Peptidic β-Secretase Inhibitor" (373).

Published TypeFieldAccessAuthorsCitations

Showing 50 of 60 papers. Every paper with more than 52 citations is listed.

Most cited papers, sortable by citations and release date
#	Paper
1	Gemcitabine alone or in combination with cisplatin in patients with biliary tract cancer: a comparative multicentre study in Japan Takuji Okusaka, Kohei Nakachi, Akira Fukutomi et al. · British Journal of Cancer Open access	13 Jul 2010	757
2	Ramucirumab plus erlotinib in patients with untreated, EGFR-mutated, advanced non-small-cell lung cancer (RELAY): a randomised, double-blind, placebo-controlled, phase 3 trial Kazuhiko Nakagawa et al. · The Lancet Oncology Open access131 authors	4 Oct 2019	619
3	Robust Central Reduction of Amyloid-β in Humans with an Orally Available, Non-Peptidic β-Secretase Inhibitor Patrick C. May et al. · Journal of Neuroscience Open access	16 Nov 2011	373
4	Safety Profile of Baricitinib in Patients with Active Rheumatoid Arthritis with over 2 Years Median Time in Treatment Josef S Smolen, Mark C. Genovese, Tsutomu Takeuchi et al. · The Journal of Rheumatology Open access	15 Sep 2018	260
5	Efficacy and safety of tirzepatide monotherapy compared with dulaglutide in Japanese patients with type 2 diabetes (SURPASS J-mono): a double-blind, multicentre, randomised, phase 3 trial Nobuya Inagaki, Masakazu Takeuchi, Tomonori Oura et al. · The Lancet Diabetes & Endocrinology Open access	30 Jul 2022	226
6	Glucagon-Like Peptide 1 Receptor Agonist or Bolus Insulin With Optimized Basal Insulin in Type 2 Diabetes Michaëla Diamant, Michael Albrecht Nauck, Rimma M. Shaginian et al. · Diabetes Care	11 Jul 2014	226
7	Efficacy and safety of ixekizumab treatment for Japanese patients with moderate to severe plaque psoriasis, erythrodermic psoriasis and generalized pustular psoriasis: Results from a 52‐week, open‐label, phase 3 study ( UNCOVER ‐J) Hidehisa Saeki, Hidemi Nakagawa, Ko Nakajo et al. · The Journal of Dermatology Open access	11 Oct 2016	195
8	Prevalence, burden, and clinical management of migraine in China, Japan, and South Korea: a comprehensive review of the literature Takao Takeshima, Qi Wan, Yanlei Zhang et al. · The Journal of Headache and Pain Open access	Dec 2019	176
9	Impact of caring for persons with Alzheimer’s disease or dementia on caregivers’ health outcomes: findings from a community based survey in Japan Amir Goren, William S. Montgomery, Kristin Kahle‐Wrobleski et al. · BMC Geriatrics Open access	10 Jun 2016	159
10	Diabetes in Japan: a review of disease burden and approaches to treatment Susan E. Neville, Kristina Secnik Boye, William S. Montgomery et al. · Diabetes/Metabolism Research and Reviews	30 Sep 2009	157
11	Pharmacogenomics of gemcitabine: can genetic studies lead to tailor-made therapy? Hideki Ueno, Kendo Kiyosawa, Nahoko Kaniwa · British Journal of Cancer Open access	26 Jun 2007	157
12	The Role of Descending Inhibitory Pathways on Chronic Pain Modulation and Clinical Implications Mikwang Kwon, Murat Altın, Héctor Dueñas et al. · Pain Practice	20 Nov 2013	153
13	Effects of teriparatide on bone mineral density and bone turnover markers in Japanese subjects with osteoporosis at high risk of fracture in a 24-month clinical study: 12-Month, randomized, placebo-controlled, double-blind and 12-month open-label phases Akimitsu Miyauchi, Toshio Matsumoto, Toshitsugu Sugimoto et al. · Bone	25 May 2010	147
14	Guidelines for the use of biochemical markers of bone turnover in osteoporosis (2004) Yoshiki Nishizawà, Toshitaka Nakamura, Hiroaki Ohta et al. · Journal of Bone and Mineral Metabolism	4 Mar 2005	138
15	Efficacy and safety of open‐label ixekizumab treatment in Japanese patients with moderate‐to‐severe plaque psoriasis, erythrodermic psoriasis and generalized pustular psoriasis Hidehisa Saeki, Hidemi Nakagawa, Taeko Ishii et al. · Journal of the European Academy of Dermatology and Venereology	30 Oct 2014	132
16	Safety and efficacy of tirzepatide as an add-on to single oral antihyperglycaemic medication in patients with type 2 diabetes in Japan (SURPASS J-combo): a multicentre, randomised, open-label, parallel-group, phase 3 trial Takashi Kadowaki, Rina Chin, Akichika Ozeki et al. · The Lancet Diabetes & Endocrinology Open access	30 Jul 2022	129
17	Randomised, double-blind, placebo-controlled study of olanzapine in patients with bipolar I depression Mauricio F. Tohen, David McDonnell, Michael G. Case et al. · The British Journal of Psychiatry Open access	24 Aug 2012	129
18	Efficacy and Safety of Baricitinib in Japanese Patients with Active Rheumatoid Arthritis Receiving Background Methotrexate Therapy: A 12-week, Double-blind, Randomized Placebo-controlled Study Yoshiya Tanaka, Kahaku Emoto, Zhihong Cai et al. · The Journal of Rheumatology Open access	Feb 2016	124
19	Residual symptoms and disease burden among patients with rheumatoid arthritis in remission or low disease activity: a systematic literature review Masato Ishida, Yuki Kuroiwa, Emiko Yoshida et al. · Modern Rheumatology ReviewOpen access	18 Dec 2017	120
20	Efficacy and Safety of Two Doses of Pemetrexed Supplemented with Folic Acid and Vitamin B12 in Previously Treated Patients with Non-Small Cell Lung Cancer Yuichiro Ohe, Yukito Ichinose, Kazuhiko Nakagawa et al. · Clinical Cancer Research	Jul 2008	120
21	Donanemab (LY3002813) Phase 1b Study in Alzheimer's Disease: Rapid and Sustained Reduction of Brain Amyloid Measured by Florbetapir F18 Imaging Stephen Loucian Lowe, Cynthia Duggan Evans, Sergey Shcherbinin et al. · The Journal of Prevention of Alzheimer s Disease Open access	15 Sep 2021	117
22	Safety and Immunogenicity of LY3415244, a Bispecific Antibody Against TIM-3 and PD-L1, in Patients With Advanced Solid Tumors Matthew David Hellmann, Nicoletta Bivi, Boris Calderón et al. · Clinical Cancer Research Open access	13 Jan 2021	113
23	A randomized, double-blind, phase II study of ramucirumab plus docetaxel vs placebo plus docetaxel in Japanese patients with stage IV non-small cell lung cancer after disease progression on platinum-based therapy Kiyotaka Yoh, Yukio Hosomi, Kazuo Kasahara et al. · Lung Cancer Open access	19 Jul 2016	113
24	Identification of peak bone mass QTL in a spontaneously osteoporotic mouse strain Motoyuki Shimizu, Keiichi Higuchi, Beth Bennett et al. · Mammalian Genome	Feb 1999	110
25	Real-world effectiveness of teriparatide on fracture reduction in patients with osteoporosis and comorbidities or risk factors for fractures: Integrated analysis of 4 prospective observational studies Bente Lomholt Langdahl, Stuart L. Silverman, Saeko Fujiwara et al. · Bone Open access	20 Jul 2018	109
26	Burden of Migraine in Japan: Results of the ObserVational Survey of the Epidemiology, tReatment, and Care Of MigrainE (OVERCOME [Japan]) Study Yasuhiko Matsumori, Kaname Ueda, Mika Komori et al. · Neurology and Therapy Open access	3 Dec 2021	107
27	Phase 1 study of galunisertib, a TGF-beta receptor I kinase inhibitor, in Japanese patients with advanced solid tumors Yutaka Fujiwara, Hiroshi Nokihara, Yasuhide Yamada et al. · Cancer Chemotherapy and Pharmacology	2 Nov 2015	100
28	Once‐weekly glucagon‐like peptide‐1 receptor agonist dulaglutide is non‐inferior to once‐daily liraglutide and superior to placebo in J apanese patients with type 2 diabetes: a 26‐week randomized phase III study Jun‐ichiro Miyagawa, Masato Odawara, Toshinari Takamura et al. · Diabetes Obesity and Metabolism Open access	14 Jul 2015	98
29	Real-world treatment patterns and patient-reported outcomes in episodic and chronic migraine in Japan: analysis of data from the Adelphi migraine disease specific programme Kaname Ueda, Wenyu Ye, Louise Lombard et al. · The Journal of Headache and Pain Open access	7 Jun 2019	96
30	Infections in baricitinib clinical trials for patients with active rheumatoid arthritis Kevin L. Winthrop, Masayoshi Harigai, Mark C. Genovese et al. · Annals of the Rheumatic Diseases Open access	11 Aug 2020	94
31	PINP as an aid for monitoring patients treated with teriparatide Mika Tsujimoto, Peiqi Chen, Akimitsu Miyauchi et al. · Bone	18 Dec 2010	93
32	Subgroup analyses of the safety and efficacy of ramucirumab in Japanese and Western patients in RAINBOW: a randomized clinical trial in second-line treatment of gastric cancer Kohei Shitara et al. · Gastric Cancer Open access	28 Oct 2015	87
33	Randomized, Double-blind, Placebo-controlled Phase III Trial of Duloxetine Monotherapy in Japanese Patients With Chronic Low Back Pain Shin‐ichi Konno, Natsuko Oda, Toshimitsu Ochiai et al. · Spine Open access	25 May 2016	85
34	Phase I study of LY2181308, an antisense oligonucleotide against survivin, in patients with advanced solid tumors Maki Tanioka, Hiroshi Nokihara, Noboru Yamamoto et al. · Cancer Chemotherapy and Pharmacology	15 Nov 2010	85
35	Efficacy and Safety Profile of Exenatide Once Weekly Compared With Insulin Once Daily in Japanese Patients With Type 2 Diabetes Treated With Oral Antidiabetes Drug(s): Results From a 26-Week, Randomized, Open-Label, Parallel-Group, Multicenter, Noninferiority Study Nobuya Inagaki, Yoshihito Atsumi, Tomonori Oura et al. · Clinical Therapeutics	9 Aug 2012	85
36	Tadalafil once daily for lower urinary tract symptoms suggestive of benign prostatic hyperplasia: A randomized placebo‐ and tamsulosin‐controlled 12‐week study in A sian men Osamu Yokoyama, Masaki Yoshida, Sae Chul Kim et al. · International Journal of Urology	7 Sep 2012	84
37	Comprehensive population-based survey of migraine in Japan: results of the ObserVational Survey of the Epidemiology, tReatment, and Care Of MigrainE (OVERCOME [Japan]) study Koichi Hirata, Kaname Ueda, Mika Komori et al. · Current Medical Research and Opinion Open access	25 Aug 2021	83
38	Efficacy and safety of once‐weekly dulaglutide in combination with sulphonylurea and/or biguanide compared with once‐daily insulin glargine in J apanese patients with type 2 diabetes: a randomized, open‐label, phase III , non‐inferiority study Eiichi Araki, Nobuya Inagaki, Yukio Tanizawa et al. · Diabetes Obesity and Metabolism Open access	14 Jul 2015	82
39	Concomitant Coronary Atheroma Regression and Stabilization in Response to Lipid-Lowering Therapy Flavio Giuseppe Biccirè et al. · Journal of the American College of Cardiology Open access	26 Aug 2023	80
40	Potentials and limitations of nonclinical safety assessment for predicting clinical adverse drug reactions: correlation analysis of 142 approved drugs in Japan Chihiro Tamaki, Takashi Nagayama, Masamichi Hashiba et al. · The Journal of Toxicological Sciences Open access	2013	80
41	Empagliflozin Induces Transient Diuresis Without Changing Long-Term Overall Fluid Balance in Japanese Patients With Type 2 Diabetes Atsutaka Yasui, Ganghyuck Lee, Tetsuaki Hirase et al. · Diabetes Therapy Open access	27 Feb 2018	79
42	The Effect of Discontinuing Treatment With Blosozumab: Follow-up Results of a Phase 2 Randomized Clinical Trial in Postmenopausal Women With Low Bone Mineral Density Christopher P. Recknor, Robert R. Recker, Charles Benson et al. · Journal of Bone and Mineral Research Open access	24 Feb 2015	77
43	Increased Risk of Acute Pancreatitis in Patients with Type 2 Diabetes: An Observational Study Using a Japanese Hospital Database Hisashi Urushihara, Masanori Taketsuna, Ying Liu et al. · PLoS ONE Open access	27 Dec 2012	75
44	An individualized GH dose regimen for long-term GH treatment in Japanese patients with adult GH deficiency Kazuo Chihara, Ekaterina B Koledova, Akira Shimatsu et al. · European Journal of Endocrinology	Jul 2005	72
45	Overexpression of IQGAP1 in advanced colorectal cancer correlates with poor prognosis—critical role in tumor invasion Hiroyuki Hayashi, Kazuki Nabeshima, Mikiko Aoki et al. · International Journal of Cancer	23 Oct 2009	66
46	Long‐term efficacy and safety of ixekizumab in Japanese patients with erythrodermic or generalized pustular psoriasis: subgroup analyses of an open‐label, phase 3 study ( UNCOVER ‐J) Yukari Okubo, Tomotaka Mabuchi, Keiji Iwatsuki et al. · Journal of the European Academy of Dermatology and Venereology Open access	14 Oct 2018	63
47	Alzheimer’s disease severity and its association with patient and caregiver quality of life in Japan: results of a community-based survey William S. Montgomery, Amir Goren, Kristin Kahle‐Wrobleski et al. · BMC Geriatrics Open access	14 Jun 2018	63
48	Epidemiology, associated burden, and current clinical practice for the diagnosis and management of Alzheimer’s disease in Japan William S. Montgomery, Kaname Ueda, Margaret Jorgensen et al. · ClinicoEconomics and Outcomes Research Open access	Dec 2017	63
49	Lifestyle-Related Metabolic Disorders, Osteoporosis, and Fracture Risk in Asia: A Systematic Review Toshitsugu Sugimoto, Masayo Sato, Francis C. Dehle et al. · Value in Health Regional Issues ReviewOpen access	4 Dec 2015	63
50	Pharmacokinetics, Pharmacodynamics, Tolerability, and Safety of Exenatide in Japanese Patients With Type 2 Diabetes Mellitus Prajakti A. Kothare, Helle Linnebjerg, Yoshitaka Isaka et al. · The Journal of Clinical Pharmacology	Dec 2008	63

Citations are OpenAlex's own counts, from its 2026-09-23 snapshot, so the ranking can differ from Google Scholar or Web of Science. A paper is listed for an institution when any of its authors gave it as an affiliation; retracted papers and papers whose citation count cannot be traced to citing works are left out, and a preprint and the article it became are shown once. Release dates are OpenAlex's: where a source gave only a month or a year, that is what is shown. How the lists are chosen.